Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.

IF 3.4 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Journal of Gynecologic Oncology Pub Date : 2024-09-01 Epub Date: 2024-01-24 DOI:10.3802/jgo.2024.35.e58

Gengwei Huo, Wenjie Liu, Peng Chen

{"title":"Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.","authors":"Gengwei Huo, Wenjie Liu, Peng Chen","doi":"10.3802/jgo.2024.35.e58","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the cost-effectiveness of tisotumab vedotin to treat recurrent or metastatic cervical cancer in second- or third-line from the U.S. payer perspective.Methods: A Markov model with three-state was employed to simulate recurrent or metastatic cervical cancer patients who were administered either tisotumab vedotin or investigator's choice of chemotherapy based on the phase III, open-labeled innovaTV 301 randomized clinical trial. The data on cost and health preferences were collected from the literature.Results: Tisotumab vedotin generated an additional 0.25 quality-adjusted life-years (QALYs) compared to chemotherapy, but at an additional cost of $206,779. This results in incremental cost-effectiveness ratios of $839,107.88 per QALY. The results of the univariate sensitivity analysis indicated that cost of tisotumab vedotin, utility of progressive disease and progression-free survival had the greatest impacts on the outcomes. Probability sensitivity analysis showed that tisotumab vedotin had a 0% chance of being considered cost-effective.Conclusion: Tisotumab vedotin was unlikely cost-effective compared to chemotherapy for recurrent or metastatic cervical cancer patients at a willingness-to-pay threshold of $150,000/QALY from the perspective of a U.S. payer. Lowering the prices of tisotumab vedotin could potentially enhance its cost-effectiveness.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e58"},"PeriodicalIF":3.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390250/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gynecologic Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3802/jgo.2024.35.e58","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the cost-effectiveness of tisotumab vedotin to treat recurrent or metastatic cervical cancer in second- or third-line from the U.S. payer perspective.

Methods: A Markov model with three-state was employed to simulate recurrent or metastatic cervical cancer patients who were administered either tisotumab vedotin or investigator's choice of chemotherapy based on the phase III, open-labeled innovaTV 301 randomized clinical trial. The data on cost and health preferences were collected from the literature.

Results: Tisotumab vedotin generated an additional 0.25 quality-adjusted life-years (QALYs) compared to chemotherapy, but at an additional cost of $206,779. This results in incremental cost-effectiveness ratios of $839,107.88 per QALY. The results of the univariate sensitivity analysis indicated that cost of tisotumab vedotin, utility of progressive disease and progression-free survival had the greatest impacts on the outcomes. Probability sensitivity analysis showed that tisotumab vedotin had a 0% chance of being considered cost-effective.

Conclusion: Tisotumab vedotin was unlikely cost-effective compared to chemotherapy for recurrent or metastatic cervical cancer patients at a willingness-to-pay threshold of $150,000/QALY from the perspective of a U.S. payer. Lowering the prices of tisotumab vedotin could potentially enhance its cost-effectiveness.

查看原文本刊更多论文

将替索单抗维多汀作为宫颈癌二线或三线疗法的成本效益。

目的从美国支付方的角度评估在二线或三线治疗复发性或转移性宫颈癌时使用替索单抗韦多汀的成本效益：采用三状态马尔可夫模型模拟复发或转移性宫颈癌患者，根据 II 期开放标签 innovaTV 301 随机临床试验结果，患者可选择使用替索单抗维多汀或研究者选择的化疗方案。有关成本和健康偏好的数据来自文献：结果：与化疗相比，替索单抗维多汀可增加0.25个质量调整生命年（QALYs），但成本增加了206779美元。因此，每 QALY 的增量成本效益比为 839,107.88 美元。单变量敏感性分析的结果表明，替索单抗维多汀的成本、进展期疾病的效用和无进展生存期对结果的影响最大。概率敏感性分析表明，利妥珠单抗维多汀被认为具有成本效益的几率为0%：结论：从美国支付方的角度来看，在支付意愿阈值为150,000美元/QALY时，与化疗相比，替索单抗维多汀治疗复发性或转移性宫颈癌患者不太可能具有成本效益。降低替索单抗维多汀的价格有可能提高其成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Gynecologic Oncology ONCOLOGY-OBSTETRICS & GYNECOLOGY

CiteScore

6.00

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of Gynecologic Oncology (JGO) is an official publication of the Asian Society of Gynecologic Oncology. Abbreviated title is ''J Gynecol Oncol''. It was launched in 1990. The JGO''s aim is to publish the highest quality manuscripts dedicated to the advancement of care of the patients with gynecologic cancer. It is an international peer-reviewed periodical journal that is published bimonthly (January, March, May, July, September, and November). Supplement numbers are at times published. The journal publishes editorials, original and review articles, correspondence, book review, etc.